The RheumNow Week in Review – 21 July 2017 Save

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

1. FDA accepts Pfizers NDA for Xeljanz (tofacitinib) as treatment for moderately to severely active ulcerative colitis https://t.co/QJi2g2Bfao
2. FDA rejects Romosuzumab (anti-Sclerostin OP Rx) w/ a complete response letter asking for resubmission, more data https://t.co/Xz8DjEMtUM
3. RA ACPA+ have higher economic burden with MORE early DMARD use (71 vs 50%) & Biologic use (20 vs 12%); more MD visits; & more Total costs https://t.co/le0vgHKaPL
4. Mucosal immunity seen in at-risk RA (preclinical) people who had more IgA producing plasmablasts (39%) than established RA or normal controls(1%, 9%) https://t.co/Bi9F2inrtb 
5. 7 patients with Active Refractory Takayasu arteritis treated with RTX showed mixed results - 3 achieved remission but 4 failed to respond to RTX. https://t.co/rXSNc6qpTn  
6. Study of 38,924 shows dairy intake assoc with an increased risk of OA hip replacement (unrelated to age, BMI, smoking, activity https://t.co/T37NXzn40B
7. 1979-2013 Septic arthritis in RA has increased and associated with more biologic use, polyarticular infections, MRSA (6% v 31%); but same outcomes https://t.co/2JNqp5n1GJ
8. Alcohol & Smoking assoc w/ 2 fold risk of Hand OA. but being overweight or obese is NOT. https://t.co/pAa2uiLa9B
9. MTX has yet to be shown to benefit Osteoarthritis; but there is a new PROMOTE trial looking at pain reduction. Still enrolling. https://t.co/yc3qSEPujJ
10. Zurampic 200mg + Uloric fails vs Uloric alone at achieving two primary endpoints SUA<5 (57% vs 47%) & topus resolution (no diff btw groups). https://t.co/LtjJyKIQ28
11. Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too 
12. Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis 
13. Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus 
14. FDA Approves Tremfya (guselkumab) for Plaque Psoriasis